Chemotherapy Strategies and Their Efficacy for Mesenchymal Chondrosarcoma
Current Oncology · 03.11.2025 · 32 (11) · 615
DOI: 10.3390/curroncol32110615 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 03.11.2025. Verfasst von Piotr Remiszewski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. Hauptthemen laut MEDLINE: Chondrosarcoma, Mesenchymal, Bone Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIO-PIB statutory PhD.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Mesenchymal chondrosarcoma (MCS) is characterised by small round cell biology, frequent HEY1-NCOA2 fusion, and high vascularity. These features plausibly lessen extracellular matrix barriers and confer relative chemosensitivity. We synthesised peri-operative (preoperative/neoadjuvant; postoperative/adjuvant) and palliative chemotherapy outcomes separately across multiple cohorts and case reports as well as the summarised the guidelines (ESMO/NCCN) In localised disease, integrating multi-agent Ewing-type chemotherapy with complete resection is associated with improved disease control. Contemporary 5-year overall survival (OS) typically spans ~55–73% across studies, while event-free survival (EFS) gains are demonstrated more consistently than OS gains in pooled analyses. In advanced MCS, first-line polychemotherapy yields modest, non-curative activity, with objective response rates (ORRs) of ~25–35% in adults, median progression-free survival (PFS) of ~4.7–6.7 months, and median OS of ~18 months. Activity may be higher in younger patients and for platinum–anthracycline combinations. We also discussed emerging therapies. Trabectedin demonstrates low disease control rate in translocation-related sarcomas, including few MCS cases. Anti-angiogenic tyrosine kinase inhibitors, such as apatinib and pazopanib, demonstrate activity in chondrosarcoma, but MCS-specific data are lacking. IDH1 inhibition benefits conventional subtypes rather than MCS. Early immunotherapy experience is limited, but pathway-directed strategies targeting BCL2 and PI3K-mTOR warrant evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
- Medical Faculty, Medical University of Warsaw, 02-781 Warsaw, Poland.
- Department of Experimental Pharmacology, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-781 Warsaw, Poland.
- Outpatient Chemotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
ORCID-Profile: Piotr Remiszewski, Julia Wąż, Piotr Rutkowski, Anna M Czarnecka
Förderung
- NIO-PIB statutory PhD
Zitieren
APA
Remiszewski, P., Wąż, J., Falkowski, S., Rutkowski, P., & Czarnecka, A. M. (2025). Chemotherapy Strategies and Their Efficacy for Mesenchymal Chondrosarcoma. Current Oncology, 32(11), 615. https://doi.org/10.3390/curroncol32110615
Vancouver
Remiszewski P, Wąż J, Falkowski S, Rutkowski P, Czarnecka AM. Chemotherapy Strategies and Their Efficacy for Mesenchymal Chondrosarcoma. Current Oncology. 2025;32(11):615. doi:10.3390/curroncol32110615
BibTeX
@article{Remiszewski2025,
author = {Remiszewski, Piotr and Wąż, Julia and Falkowski, Sławomir and Rutkowski, Piotr and Czarnecka, Anna M},
title = {Chemotherapy Strategies and Their Efficacy for Mesenchymal Chondrosarcoma},
journal = {Current Oncology},
year = {2025},
volume = {32},
number = {11},
pages = {615},
doi = {10.3390/curroncol32110615}
}
EUVIMED